With its cheap multiple and serious upside potential, Cramer thinks this stock could give your portfolio a kick.
Cramer said that although the stock has already gained 15% in the last month, he still thinks it's cheap. "Despite that gain, Jazz still sells for just 9 times next year's earnings estimates, yet it has a 16% long-term growth rate."
Of course the natural question is - why does Jazz have such a cheap multiple? Cramer's parsed through the research and he's found that Jazz has a dark cloud hanging over it.
"The company gets 69% of its sales from a narcolepsy drug called Xyrem. Although the patent doesn't expire until 2019 a rival company, Roxane Labs, is developing what equates to a generic version," Cramer said.
"This is something that terrifies investors, because if generic Xyrem hits the market, then more than half of Jazz's revenues will be at risk," added Cramer.